Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis.

Autor:	Lin C; International Agency for Research on Cancer, Lyon, France; National Cancer Center, National Clinical Research Center for Cancer, and Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Slama J; Department of Gynecology and Obstetrics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic., Gonzalez P; Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica., Goodman MT; Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA., Xia N; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China., Kreimer AR; National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Wu T; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China., Hessol NA; University of California, San Francisco, CA, USA., Shvetsov Y; University of Hawaii Cancer Center, Honolulu, Hawaii, USA., Ortiz AP; University of Puerto Rico Comprehensive Cancer Center, Department of Biostatistics and Epidemiology, Graduate School of Public Health, UPR, San Juan, Puerto Rico., Grinsztejn B; Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil., Moscicki AB; David Geffen School of Medicine, University of California, Los Angeles, CA, USA., Heard I; Department of Endocrinology and Reproductive Medicine, IE3M, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique, Hôpitaux de Paris, Paris, France., Del Refugio González Losa M; Dr Hideyo Noguchy Center of Regional Investigations, Autonomous University of Yucatán, Mérida, Yucatán, México., Kojic EM; Mount Sinai West and St Luke's Hospitals, New York, NY, USA., Schim van der Loeff MF; Department of Infectious Diseases, Infectious Diseases Research & Prevention, GGD Amsterdam, Netherlands., Wei F; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China., Longatto-Filho A; Research Institute of Life and Health Sciences, School of Medicine, University of Minho, Braga, Portugal; 3B's (Biomaterials, Biodegradables and Biomimetics) Research Group, Portugal Government Associate Laboratory, Braga, Portugal; Laboratory of Medical Investigation 14, Department of Pathology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil; Teaching and Research Institute, Molecular Oncology Research Center, Barretos Cancer Hospital-Pio XII Foundation, Barretos, Brazil., Mbulawa ZA; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Department of Pathology, Division of Medical Virology, University of Cape Town, Cape Town, South Africa; Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa; South African Medical Research Council Gynaecological Cancer Research Centre, University of Cape Town, Cape Town, South Africa., Palefsky JM; University of California, San Francisco, CA, USA., Sohn AH; TREAT Asia/amfAR-Foundation for AIDS Research, Thai Red Cross AIDS Research Centre, Bangkok, Thailand., Hernandez BY; University of Hawaii Cancer Center, Honolulu, Hawaii, USA., Robison K; Obstetrics & Gynecology and Medicine, The Warren Alpert Medical School of Brown University, Providence, RI, USA., Simpson S Jr; Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia., Conley LJ; Division of HIV/AIDS Prevention, Epidemiology Research Team, Centers for Disease Control and Prevention, Atlanta, GA, USA., de Pokomandy A; Chronic Viral Illness Service, McGill University Health Centre and Department of Family Medicine, McGill University, Montreal, QC, Canada., van der Sande MAB; Public Health Epidemiology, Head Department Public Health, Institute of Tropical Medicine, Antwerp, Belgium., Dube Mandishora RS; Department of Medical Microbiology, University of Zimbabwe College of Health Sciences, Parirenyatwa Hospital premises, Harare, Zimbabwe., Volpini LPB; Health Sciences Center, Federal University of Espírito Santo, Vitória, Brazil., Pierangeli A; Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy., Romero B; Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica., Wilkin T; Weill Cornell Medicine, New York, NY, USA., Franceschi S; Aviano Cancer Center, Aviano, Italy., Hidalgo-Tenorio C; Infectious Diseases Service, University Hospital Virgen de las Nieves, Granada, Spain., Ramautarsing RA; Thai Red Cross AIDS Research Centre, Bangkok, Thailand., Park IU; Department of Family and Community Medicine, University of California San Francisco School of Medicine, San Francisco, CA, USA., Tso FK; Department of Gynecology of the Federal University of São Paulo, São Paulo, Brazil., Godbole S; Division of Epidemiology and Biostatistics, ICMR-National AIDS Research Institute, Indian Council of Medical Research, Pune, India., D'Hauwers KWM; Radboud University Nijmegen, Medical Centre, Department of Urology, Nijmegen, Netherlands., Sehnal B; Department of Gynecology and Obstetrics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic., Menezes LJ; Division of Infectious Disease, University of South Florida, Tampa, FL, USA., Heráclio SA; Women's Healthcare Center, Instituto de Medicina Integral Professor Fernando Figueira, Recife, PE, Brazil; Cytopathology Division, Public Health Laboratory of the State of Pernambuco, Recife, PE, Brazil., Clifford GM; International Agency for Research on Cancer, Lyon, France. Electronic address: cliffordg@iarc.fr.
Jazyk:	angličtina
Zdroj:	The Lancet. Infectious diseases [Lancet Infect Dis] 2019 Aug; Vol. 19 (8), pp. 880-891. Date of Electronic Publication: 2019 Jun 13.
DOI:	10.1016/S1473-3099(19)30164-1
Abstrakt:	Background: Cervical cancer screening might contribute to the prevention of anal cancer in women. We aimed to investigate if routine cervical cancer screening results-namely high-risk human papillomavirus (HPV) infection and cytohistopathology-predict anal HPV16 infection, anal high-grade squamous intraepithelial lesions (HSIL) and, hence, anal cancer. Methods: We did a systematic review of MEDLINE, Embase, and the Cochrane library for studies of cervical determinants of anal HPV and HSIL published up to Aug 31, 2018. We centrally reanalysed individual-level data from 13 427 women with paired cervical and anal samples from 36 studies. We compared anal high-risk HPV prevalence by HIV status, cervical high-risk HPV, cervical cytohistopathology, age, and their combinations, using prevalence ratios (PR) and 95% CIs. Among 3255 women with anal cytohistopathology results, PRs were similarly calculated for all anal HSIL and HPV16-positive anal HSIL. Findings: Cervical and anal HPV infections were highly correlated. In HIV-negative women, anal HPV16 prevalence was 41% (447/1097) in cervical HPV16-positive versus 2% (214/8663) in cervical HPV16-negative women (PR 16·5, 95% CI 14·2-19·2, p<0·0001); these values were 46% (125/273) versus 11% (272/2588) in HIV-positive women (4·4, 3·7-5·3, p<0·0001). Anal HPV16 was also associated with cervical cytohistopathology, with a prevalence of 44% [101/228] for cervical cancer in HIV-negative women (PR vs normal cytology 14·1, 11·1-17·9, p<0·0001). Anal HSIL was associated with cervical high-risk HPV, both in HIV-negative women (from 2% [11/527] in cervical high-risk HPV-negative women up to 24% [33/138] in cervical HPV16-positive women; PR 12·9, 95% CI 6·7-24·8, p<0·0001) and HIV-positive women (from 8% [84/1094] to 17% [31/186]; 2·3, 1·6-3·4, p<0·0001). Anal HSIL was also associated with cervical cytohistopathology, both in HIV-negative women (from 1% [5/498] in normal cytology up to 22% [59/273] in cervical HSIL; PR 23·1, 9·4-57·0, p<0·0001) and HIV-positive women (from 7% [105/1421] to 25% [25/101]; 3·6, 2·5-5·3, p<0·0001). Prevalence of HPV16-positive anal HSIL was 23-25% in cervical HPV16-positive women older than 45 years (5/20 in HIV-negative women, 12/52 in HIV-positive women). Interpretation: HPV-based cervical cancer screening programmes might help to stratify anal cancer risk, irrespective of HIV status. For targeted secondary anal cancer prevention in high-risk groups, HIV-negative women with cervical HPV16, especially those older than 45 years, have a similar anal cancer risk profile to that of HIV-positive women. Funding: International Agency for Research on Cancer. (Copyright © 2019 International Agency for Research on Cancer; licensee Elsevier. This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that IARC endorses any specific organisation, products or services. The use of the IARC logo is not permitted. This notice should be preserved along with the article's original URL.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu